Our analysis is based on comparing STERIS Plc with the following peers – Hill-Rom Holdings, Inc., Stryker Corporation, Cantel Medical Corp., Invacare Corporation, Thermo Fisher Scientific Inc., Owens & Minor, Inc., Johnson & Johnson, CONMED Corporation, Ecolab Inc. and 3M Company (HRC-US, SYK-US, CMD-US, IVC-US, TMO-US, OMI-US, JNJ-US, CNMD-US, ECL-US and MMM-US).
STERIS Plc’s dividend yield is 1.54 percent and its dividend payout is 52.55 percent. This compares to a peer median dividend yield of 1.29 percent and a payout level of 38.89 percent. This type of dividend performance might make it a good stock for dividend investors. In addition, the company’s relatively good dividend quality score of 67 out of a possible score of 100 points to some sustainability of its robust payout ratio, and underscores its attractiveness for dividend investors seeking current income.
Dividend Quality Overview
- Over the last twelve months (prior to September 30, 2016), STE-US paid a medium quality dividend, which represents a yield of 1.50% at the current price.
- Dividend quality trend has not been consistent over the last five years. Dividends were paid during each of these years — of these 2 were high quality, 2 were medium quality and 1 was low quality.
- The ending cash balance, with a dividend coverage of 3.10x, provides a substantial cushion in case of a significant reduction of cash flows in the future.
Quadrant label definitions. Hover to know more
Over the last twelve months (prior to September 30, 2016), STE-US paid a medium quality dividend.
The source of the company’s cash to support the dividend paid over the last twelve months is operating cash flow (coverage of 4.43x), investing cash flow (coverage of -5.82x), issuance cash flow (coverage of 3.68x) and twelve-month prior cash (coverage of 1.98x), for a total dividend coverage of 4.10x.
STE-US‘s issuance cash flow includes outflows from net share buybacks (coverage of -0.61x). Thus, the total coverage including share buybacks is 4.71x, which reflects our assumption that the cash paid for share buybacks is discretionary and could instead be used to pay dividends.
These coverage ratio factors imply that the firm’s net cash inflow from issuance was required (in addition to operating and investment cash) to pay the dividend, which suggests a medium dividend quality.
|Dividend Yield (%)||2.11||1.77||1.72||1.28||1.07||1.54|
|Dividend Payout (%)||28.57||27.21||37.79||40||62.82||52.55|
A complete list of metrics and analysis is available on the company page.
STERIS Plc engages in the manufacture of surgical and other medical supplies. It operates through the following segments: Healthcare Products, Healthcare Specialty Services, Life Sciences and Applied Sterilization Technologies. The Healthcare Products segment offers infection prevention and procedural solutions for healthcare providers worldwide, including capital equipment and related maintenance and installation services, as well as consumables. The Healthcare Specialty Services segment provides a range of specialty services for healthcare providers including hospital sterilization services, instrument and scope repairs, and linen management. The Life Sciences segment offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities. The Applied Sterilization Technologies segment offers a contract sterilization and laboratory services for medical device and pharmaceutical Customers and others. The company was founded on October 9, 2014 and is headquartered in Leicester, United Kingdom.
The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party’s use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any our reports, you’re agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website www.analytixinsight.com.